3D Medicines, Inc. (HK:1244) has released an update.
3D Medicines Inc., in their supplemental announcement, detailed the allocation and usage of proceeds from their Global Offering after their December 2022 listing on The Stock Exchange of Hong Kong Limited. A significant majority of the proceeds, 90%, is dedicated to research, development, and commercialization of their products, including envafolimab and other drug candidates, with a timeline extending to December 2025. The remaining funds are allocated to general corporate and working capital purposes.
For further insights into HK:1244 stock, check out TipRanks’ Stock Analysis page.
